组蛋白去乙酰化酶抑制剂伏立诺他联合放疗治疗转移性神经母细胞瘤：疗效和潜在机制。
Cooperation of the HDAC inhibitor vorinostat and radiation in metastatic neuroblastoma: efficacy and underlying mechanisms.
机构信息
Department of Neurology, University of California, San Francisco, 505 Parnassus Avenue, San Francisco, CA 94143-0106, USA.
出版信息
Cancer Lett. 2011 Jul 28;306(2):223-9. doi: 10.1016/j.canlet.2011.03.010. Epub 2011 Apr 16.
Abstract
Histone deacetylase (HDAC) inhibitors can radiosensitize cancer cells. Radiation is critical in high-risk neuroblastoma treatment, and combinations of HDAC inhibitor vorinostat and radiation are proposed for neuroblastoma trials. Therefore, we investigated radiosensitizing effects of vorinostat in neuroblastoma. Treatment of neuroblastoma cell lines decreased cell viability and resulted in additive effects with radiation. In a murine metastatic neuroblastoma in vivo model vorinostat and radiation combinations decreased tumor volumes compared to single modality. DNA repair enzyme Ku-86 was reduced in several neuroblastoma cells treated with vorinostat. Thus, vorinostat potentiates anti-neoplastic effects of radiation in neuroblastoma possibly due to down-regulation of DNA repair enzyme Ku-86.
摘要
组蛋白去乙酰化酶（HDAC）抑制剂可以使癌细胞对放射敏感。放射治疗在高危神经母细胞瘤的治疗中至关重要，因此提议将 HDAC 抑制剂伏立诺他和放射治疗联合应用于神经母细胞瘤的临床试验。因此，我们研究了伏立诺他在神经母细胞瘤中的放射增敏作用。用伏立诺他处理神经母细胞瘤细胞系会降低细胞活力，并与放射治疗产生相加作用。在一种鼠转移性神经母细胞瘤的体内模型中，与单一治疗方式相比，伏立诺他和放射治疗联合治疗可降低肿瘤体积。用伏立诺他处理几种神经母细胞瘤细胞后，DNA 修复酶 Ku-86 减少。因此，伏立诺他增强了神经母细胞瘤中放射治疗的抗肿瘤作用，可能是由于 DNA 修复酶 Ku-86 的下调。
相似文献
1
Cooperation of the HDAC inhibitor vorinostat and radiation in metastatic neuroblastoma: efficacy and underlying mechanisms.
Cancer Lett. 2011 Jul 28;306(2):223-9. doi: 10.1016/j.canlet.2011.03.010. Epub 2011 Apr 16.
2
Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci.
Mol Cancer Ther. 2006 Aug;5(8):1967-74. doi: 10.1158/1535-7163.MCT-06-0022.
3
Vorinostat enhances the radiosensitivity of a breast cancer brain metastatic cell line grown in vitro and as intracranial xenografts.
Mol Cancer Ther. 2009 Jun;8(6):1589-95. doi: 10.1158/1535-7163.MCT-09-0038. Epub 2009 Jun 9.
4
Efficacy of class I and II vs class III histone deacetylase inhibitors in neuroblastoma.
J Pediatr Surg. 2012 Jun;47(6):1267-71. doi: 10.1016/j.jpedsurg.2012.03.039.
5
A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.
Biochem Pharmacol. 2014 Aug 1;90(3):320-30. doi: 10.1016/j.bcp.2014.06.001. Epub 2014 Jun 7.
6
Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity.
Clin Cancer Res. 2005 Jul 1;11(13):4912-22. doi: 10.1158/1078-0432.CCR-04-2088.
7
Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, enhances radiosensitivity and suppresses lung metastasis in breast cancer in vitro and in vivo.
PLoS One. 2013 Oct 10;8(10):e76340. doi: 10.1371/journal.pone.0076340. eCollection 2013.
8
Histone Deacetylase (HDAC) Inhibition Induces IκB Kinase (IKK)-dependent Interleukin-8/CXCL8 Expression in Ovarian Cancer Cells.
J Biol Chem. 2017 Mar 24;292(12):5043-5054. doi: 10.1074/jbc.M116.771014. Epub 2017 Feb 6.
9
Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells.
Cancer Sci. 2016 Jul;107(7):955-62. doi: 10.1111/cas.12957. Epub 2016 Jun 13.
10
Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer and induces DNA double-strand breaks.
Clin Cancer Res. 2009 Oct 1;15(19):6148-57. doi: 10.1158/1078-0432.CCR-09-1039. Epub 2009 Sep 29.
引用本文的文献
1
Epigenetic drugs in cancer therapy.
Cancer Metastasis Rev. 2025 Feb 26;44(1):37. doi: 10.1007/s10555-025-10253-7.
2
Theranostics for Neuroblastoma: Making Molecular Radiotherapy Work Better.
J Nucl Med. 2025 Apr 1;66(4):490-496. doi: 10.2967/jnumed.124.269121.
3
Stochasticity of anticancer mechanisms underlying clinical effectiveness of vorinostat.
Heliyon. 2024 Jun 18;10(12):e33052. doi: 10.1016/j.heliyon.2024.e33052. eCollection 2024 Jun 30.
4
Aurora Kinase A inhibition enhances DNA damage and tumor cell death with I-MIBG therapy in high-risk neuroblastoma.
EJNMMI Res. 2024 Jun 13;14(1):54. doi: 10.1186/s13550-024-01112-7.
5
Molecular mechanisms of extracellular-ATP-mediated colorectal cancer progression: Implication of purinergic receptors-mediated nucleocytoplasmic shuttling of HuR.
Purinergic Signal. 2024 Dec;20(6):669-680. doi: 10.1007/s11302-024-10021-2. Epub 2024 May 27.
6
Mechanistic Sequence of Histone Deacetylase Inhibitors and Radiation Treatment: An Overview.
Pharmaceuticals (Basel). 2024 May 8;17(5):602. doi: 10.3390/ph17050602.
7
UBE4B interacts with the ITCH E3 ubiquitin ligase to induce Ku70 and c-FLIPL polyubiquitination and enhanced neuroblastoma apoptosis.
Cell Death Dis. 2023 Nov 13;14(11):739. doi: 10.1038/s41419-023-06252-7.
8
Norepinephrine transporter and vesicular monoamine transporter 2 tumor expression as a predictor of response to I-MIBG in patients with relapsed/refractory neuroblastoma.
Pediatr Blood Cancer. 2024 Jan;71(1):e30743. doi: 10.1002/pbc.30743. Epub 2023 Oct 26.
9
Recent advances in epigenetic anticancer therapeutics and future perspectives.
Front Genet. 2023 Jan 4;13:1085391. doi: 10.3389/fgene.2022.1085391. eCollection 2022.
10
The paradigm of drug resistance in cancer: an epigenetic perspective.
Biosci Rep. 2022 Apr 29;42(4). doi: 10.1042/BSR20211812.
本文引用的文献
1
Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair.
Proc Natl Acad Sci U S A. 2010 Aug 17;107(33):14639-44. doi: 10.1073/pnas.1008522107. Epub 2010 Aug 2.
2
Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study.
Lancet Oncol. 2010 May;11(5):459-64. doi: 10.1016/S1470-2045(10)70058-9. Epub 2010 Apr 6.
3
Vorinostat enhances the radiosensitivity of a breast cancer brain metastatic cell line grown in vitro and as intracranial xenografts.
Mol Cancer Ther. 2009 Jun;8(6):1589-95. doi: 10.1158/1535-7163.MCT-09-0038. Epub 2009 Jun 9.
4
Radiosensitization by SAHA in experimental colorectal carcinoma models-in vivo effects and relevance of histone acetylation status.
Int J Radiat Oncol Biol Phys. 2009 Jun 1;74(2):546-52. doi: 10.1016/j.ijrobp.2009.01.068.
5
IFN-beta sensitizes neuroblastoma to the antitumor activity of temozolomide by modulating O6-methylguanine DNA methyltransferase expression.
Mol Cancer Ther. 2008 Dec;7(12):3852-8. doi: 10.1158/1535-7163.MCT-08-0806. Epub 2008 Dec 3.
6
Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma.
Nucl Med Biol. 2008 Aug;35 Suppl 1(Suppl 1):S35-48. doi: 10.1016/j.nucmedbio.2008.05.002.
7
HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination.
Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19482-7. doi: 10.1073/pnas.0707828104. Epub 2007 Nov 27.
8
In vivo bioluminescence imaging for early detection and monitoring of disease progression in a murine model of neuroblastoma.
J Pediatr Surg. 2007 Jul;42(7):1172-9. doi: 10.1016/j.jpedsurg.2007.02.027.
9
Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies.
Clin Cancer Res. 2007 Jun 15;13(12):3605-10. doi: 10.1158/1078-0432.CCR-07-0162. Epub 2007 May 17.
10
Clonogenic assay of cells in vitro.
Nat Protoc. 2006;1(5):2315-9. doi: 10.1038/nprot.2006.339.
Zotero 插件